Clinical Trial Update: A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

Phase 4, double-blind, placebo-controlled, crossover trial evaluating Aclidinium Bromide 400 μg BID on COPD symptoms and sleep quality after 3 weeks; results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide (Aclidinium bromide)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Status: COMPLETED | Results posted: 2016-11-09